- Dihydrotanshinone I
-
-
2023-02-24
- CAS:87205-99-0
- Min. Order: 5mg
- Purity: ≥98%(HPLC)
- Supply Ability: 10 g
|
| | Dihydrotanshinone I Basic information |
| Product Name: | Dihydrotanshinone I | | Synonyms: | (-)-1,2-Dihydro-1,6-dimethylphenanthro[1,2-b]furan-10,11-dione;Dihydrotanshinone I 87205-99-0;1,6-Dimethyl-1,2,10,11-tetrahydrophenanthro[1,2-b]furan-10,11-dione;4,17-Dimethyl-15-oxagona-1,3,5(10),6,8,13-hexene-11,12-dione;Dihydrotanshinone Ⅰ, froM Salvia Miltiorrhiza;(1R)-1,6-diMethyl-1,2-dihydronaphtho[1,2-g][1]benzofuran-10,11-dione;Dihydrotanshinone I;15,16-Dihydrotanshine I | | CAS: | 87205-99-0 | | MF: | C18H14O3 | | MW: | 278.3 | | EINECS: | | | Product Categories: | chemical reagent;pharmaceutical intermediate;phytochemical;reference standards from Chinese medicinal herbs (TCM).;standardized herbal extract | | Mol File: | 87205-99-0.mol |  |
| | Dihydrotanshinone I Chemical Properties |
| Melting point | 214.0 to 218.0 °C | | Boiling point | 479.2±45.0 °C(Predicted) | | density | 1.32±0.1 g/cm3(Predicted) | | storage temp. | 2-8°C | | solubility | ethanol: soluble1mg/mL, clear, orange to red | | form | powder | | color | red | | biological source | Salvia miltiorrhiza | | λmax | 239nm(lit.) | | Henry's Law Constant | 7.6×104 mol/(m3Pa) at 25℃, HSDB (2015) | | Major Application | metabolomics
vitamins, nutraceuticals, and natural products | | InChI | 1S/C18H14O3/c1-9-4-3-5-12-11(9)6-7-13-15(12)17(20)16(19)14-10(2)8-21-18(13)14/h3-7,10H,8H2,1-2H3/t10-/m0/s1 | | InChIKey | HARGZZNYNSYSGJ-JTQLQIEISA-N | | SMILES | C[C@H]1COC(C2=C3C4=C(C=C2)C(C)=CC=C4)=C1C(C3=O)=O |
| | Dihydrotanshinone I Usage And Synthesis |
| Chemical Properties | Red powder | | Uses | Dihydrotanshinone I, an extract from Salvia miltiorrhiza Bunge, is an anti-cancer agent which has been shown to induce apoptosis in human colorectal cancer cells. | | Definition | ChEBI: Dihydrotanshinone I is an abietane diterpenoid. It has a role as an anticoronaviral agent. | | Biological Activity | Tanshinone extracted from a herb, Salvia miltiorrhiza, commonly used in Chinese traditional medicine. A significant decrease in tumor growth was observed using dihydrotanshinone I and irradiation treatment with mouse xenograft model. | | in vivo | Dihydrotanshinone I (10 and 25 mg/kg) significantly attenuates atherosclerotic plaque formation, alteres serum lipid profile, decreases oxidative stress and shrinks necrotic core areas in ApoE-/- mice. Dihydrotanshinone I dramatically inhibits the enhanced expression of LOX-1, NOX4, and NF-κB in aorta[1].
Dihydrotanshinone I (1, 2, 4 mg/kg) treatment can improve cardiac function, reduce infarct size, ameliorate the variations in myocardial zymogram and histopathological disorders, decrease 20-HETE generation, and regulate apoptosis-related protein in myocardial ischemia-reperfusion rats[2]. |
| | Dihydrotanshinone I Preparation Products And Raw materials |
|